Eli Lilly Wins First Approval in China for Oral GLP-1 Weight-Loss Pill
China approved Eli Lilly’s orforglipron pill for weight loss, giving it an early lead over Novo Nordisk in the world’s second-largest drug market.
China approved Eli Lilly’s orforglipron pill for weight loss, giving it an early lead over Novo Nordisk in the world’s second-largest drug market.
Strong Wegovy pill sales helped Novo Nordisk beat forecasts and lift its full-year 2026 sales and profit guidance for the third time.
VK2735 shows rapid weight loss in Phase 2, with financing through 2027.
The deal adds HRS-1596 to Novo’s pipeline as Lilly, daily pills and other oral GLP-1s intensify competition in obesity and diabetes.
MediciNova fell after mixed Phase 2 data for MN-001. HDL rose, but week-24 liver fat and triglycerides missed significance in 40 patients.
FDA clears Lilly’s Onswik, a once-weekly basal insulin for adults with type 2 diabetes. It may cut 300+ shots a year and now competes with Novo’s Awiqli.